These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24342747)

  • 21. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure.
    Echarri A; Castro J; Barreiro M; Carpio D; Pereira S; Lorenzo A
    J Crohns Colitis; 2010 Dec; 4(6):654-60. PubMed ID: 21122576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 23. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 24. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
    Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing biological therapy in Crohn's disease.
    Gecse KB; Végh Z; Lakatos PL
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukoapheresis in Crohn's disease: the final curtain?
    Peyrin-Biroulet L; Danese S
    Gut; 2013 Apr; 62(4):487-8. PubMed ID: 22892296
    [No Abstract]   [Full Text] [Related]  

  • 27. Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
    Hirten R; Longman RS; Bosworth BP; Steinlauf A; Scherl E
    Am J Gastroenterol; 2015 Dec; 110(12):1737-8. PubMed ID: 26673509
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
    Feagan BG; Sandborn WJ; Wolf DC; Coteur G; Purcaru O; Brabant Y; Rutgeerts PJ
    Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab in Crohn's disease.
    Rodrigo Saéz L
    Rev Esp Enferm Dig; 2004 Jun; 96(6):359-63; 364-8. PubMed ID: 15230665
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab and Crohn's QOL.
    Wicks AC; Thomas C; Curran R; Mayberry JF
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1831-2. PubMed ID: 12269979
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of oesophageal Crohn's disease with infliximab.
    Theodoropoulou A; Koutroubakis IE; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2004 Apr; 16(4):431-2. PubMed ID: 15028980
    [No Abstract]   [Full Text] [Related]  

  • 34. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
    Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of infliximab in South-east Asian children with severe Crohn's disease.
    Lee WS
    Pediatr Int; 2004 Apr; 46(2):198-201. PubMed ID: 15056252
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
    Shivashankar R; Pardi DS
    Gastroenterol Clin North Am; 2017 Sep; 46(3):589-601. PubMed ID: 28838417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful use of infliximab for perianal Crohn's disease in pregnancy.
    Chaparro M; Gisbert JP
    Inflamm Bowel Dis; 2011 Mar; 17(3):868-9. PubMed ID: 20564533
    [No Abstract]   [Full Text] [Related]  

  • 39. Evidence for the clinical use of infliximab in Crohn's disease.
    Turner SM; Probert CS
    Rom J Gastroenterol; 2003 Mar; 12(1):2-5. PubMed ID: 12673372
    [No Abstract]   [Full Text] [Related]  

  • 40. [Long-term efficacy and predictors of response to infliximab in Korean patients with Crohn's disease].
    Lee KM
    Korean J Gastroenterol; 2013 May; 61(5):241-5. PubMed ID: 23905245
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.